Table 2:
Perioperative and Treatment Characteristics
| Variables | TNT % (n) | SAND % (n) | p Value |
|---|---|---|---|
| Peritoneal Carcinomatosis Index (mean ± std) | 11.4 ± 4.9 | 10.2 ± 6.7 | 0.78 |
| Completion of Cytoreduction Score | 0.56 | ||
| 0 | 85.3 % (29) | 75.6% (34) | |
| 1 | 8.8% (3) | 15.5% (7) | |
| 2 | 5.9% (2) | 8.9% (4) | |
| Intra-operative Chemotherapy Regimen | |||
| Mitomycin C | 100% (34) | 100% (45) | 1.0 |
| Neoadjuvant Chemotherapy Regimen 0.88 | |||
| FOLFOX + Bevacizumab | 55.9% (19) | 53.3% (24) | |
| FOLFOX | 23.6% (8) | 31% (14) | |
| FOLFIRI + Bevacizumab | 11.8% (4) | 6.7% (3) | |
| FOLFIRI | 5.9% (2) | 4.5% (2) | |
| CAPE-OX | 2.8% (1) | 4.5% (2) | |
| Unplanned Hospital Admission during neoadjuvant chemotherapy | 26.5% (9) | 15.6% (7) | 0.27 |
| {80Time between Chemotherapy and Surgery (mean ± std) | 7.4 ± 3.2 weeks | 4.1 ± 2.0 weeks | 0.04 |
| ICU Admission | 8.8% (3) | 13.3% (6) | 0.73 |
| Hospital Length of Stay (mean ± std) | 8.3 ± 1.8 days | 8.9 ± 2.1 days | 0.34 |
| Adjuvant Chemotherapy Regimen | - | ||
| FOLFOX + Bevacizumab | - | 62.3% (28) | |
| FOLFOX | - | 22.2% (10) | |
| FOLFIRI + Bevacizumab | - | 11.1% (5) | |
| FOLFIRI | - | 2.2% (1) | |
| CAPE-OX | - | 2.2% (1) | |
| Completion of Adjuvant Chemotherapy Regimen | - | 71.1% (32) | |
| Unplanned Hospital re-admission | 14.7% (5) | 35.5re% (16) | 0.04 |